MedTrace Logo

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

NCT02237937 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-09-12

No results posted yet for this study

Summary

The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.

Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.

Conditions

Interventions

DRUG

Paroxetine

DRUG

Sertraline

DRUG

Citalopram

DRUG

Venlafaxine

DRUG

Amitriptyline

DRUG

Escitalopram

DRUG

Amitriptylinoxide

DRUG

Nortriptyline

DRUG

Trimipramine

Sponsors & Collaborators

  • Max-Planck-Institute of Psychiatry

    collaborator OTHER

  • HolsboerMaschmeyer NeuroChemie GmbH

    lead INDUSTRY

Principal Investigators

  • Florian Holsboer, MD, PHD · Max-Planck-Institute of Psychiatry

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237937 on ClinicalTrials.gov